Outcomes of Patients with Central Nervous System Complications After Allogeneic Hematopoietic Stem Cell Transplantation  by Akhtari, Mojtaba et al.
Biol Blood Marrow Transplant 19 (2013) S211eS232POSTER SESSION 1: LATE EFFECTS/QUALITY OF LIFE/
PSYCHOSOCIAL ISSUES196
Outcomes of Patients with Central Nervous System
Complications After Allogeneic Hematopoietic Stem Cell
Transplantation
Mojtaba Akhtari 1, Jagar Jasem 2, James O. Armitage 3,
Vamshi K.S. Balasetti 4, Philip J. Bierman 5, Edward A. Faber 6,
Pierre Fayad 7, Abdul Hadi 8, Fausto Rodriguez Loberiza 9,
Lori Maness 10, Armando D.A. Rosales 2, Julie M. Vose 11,
Robert G. Bociek 10. 1 Internal medicine, University of Nebraska
Medical Center, Omaha, NE; 2 College of Public Health,
University of Nebraska Medical Center; 3 Internal Medicine,
University of Nebraska Medical Center, Omaha, NE; 4 Internal
medicine, University of Nebraska Medical Center; 5 Department
of Internal Medicine, BMT, University of Nebraska Medical
Center, Omaha, NE; 6 University of Nebraska Medical Center;
7 Department of Neurological Sciences, University of Nebraska
Medical Center (UNMC); 8 University of Nebraska Medical
Center, Omaha, NE; 9 Univ of Nebraska Med Ctr, Omaha, NE;
10 Oncology/Hematology, University of Nebraska Medical
Center, Omaha, NE; 11Hematology/Oncology, University of
Nebraska Medical Center, Omaha, NE
Background: Allogeneic hematopoietic stem cell trans-
plantation (AHSCT) is a common treatment modality for
patients (pts) with hematological disorders. We present
a retrospective review of the incidence and impact on
outcomes of central nervous system complications (CNSCs)
in a cohort of pts with hematological disorders undergoing
AHSCT, treated at a single institution.
Methods: 351 pts with hematological disorders who
received AHSCT between 2002 and 2011 at an academic
medical center were identiﬁed. Events that were considered
CNSCs included seizures, transient ischemic attack, intra-
cranial hemorrhage, ischemic stroke, subarachnoid hemor-
rhage, subdural hematoma, meningitis, and posterior
reversible encephalopathy syndrome (PRES). Data were ob-
tained from a review of the databases and medical records.
Patient-, disease- and transplant-related characteristics
were compared between pts with or without CNSCs.
Cumulative incidence of having CNSCs were estimated using
death as competing risk. Multivariate Cox proportional
hazard regression analysis was used to compare the risk of
mortality between pts with or without CNSCs while adjust-
ing for prognostic factors. Prognostic factors considered
included: age, sex, disease type, disease stage at transplant,
donor-recipient sex-match, cmv status, type of transplant,
level of antigen matching, graft type, year of transplant, use
of total body irradiation, and prior exposure to cytarabine or
cranial irradiation.
Results: Of the 351 pts identiﬁed, forty-ﬁve pts developed
CNSCs (12.8%). No differences in patient-, disease- and
transplant-related characterisitcs were noted between those
with or without CNSCs. The 100-day cumulative incidence of
CNSCs was 8% (95% conﬁdence interval [CI] 8-15%). The most
commonly observed CNSCs included: PRES 18 (40%), stroke
or TIA 11 (24%), seizures 9 (20%), and infection 4 (9%). In
univariate analysis, there was a difference in overall survival
(OS) according to CNSCs (log-rank P ¼ .0002). The OS at 5
years for pts with CNSCs was 14% (3-32) vs. 44% for pts
without CNSCs (P-value 0.0004). In multivariate analysis, the
risk of mortality for pts with CNSCs after AHSCT
was signiﬁcantly higher, hazard ratio (HR) 1.56 (95% CI1.03 e 2.36, P ¼ .04) compared to pts without CNSCs. Other
prognostic factors identiﬁed included: sex, disease type,
disease stage at transplant, level of antigen matching. Inter-
estingly, prior history of high dose cytarabine was also
associated with higher mortality, HR 2.19 (95% CI 1.51e3.18),
P < .0001.
Conclusion: The incidence of CNSCs after AHSCT is associ-
ated with reduced survival. Identifying pts at risk, moni-
toring, early identiﬁcation, and treatment for CNSCs post
AHSCT is needed to help alter the negative impact on out-
comes.
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Background: There is a paucity of knowledge regarding the
incidence and predictors of late-occurring cirrhosis that may
be due to early post-HCT hepatic complications or late-
occurring risk factors such as iron overload, chronic GvHD, or
persistent infectious hepatitis in HCT survivors; furthermore,
there is limited information regarding the epidemiology of
cirrhosis in HCT survivors after the implementation of
universal blood product screening for Hepatitis C in 1992.
Methods: Individuals with late-occurring (1 year post-
HCT) cirrhosis, utilizing World Health Organization criteria,
were selected from 1+year survivors of allogeneic HCT per-
formed at a single institution between 1976 and 2007. The
National Hospital Discharge Survey was used to compare the
HCT cohort with age-, sex-, and HCT year-speciﬁc rates of
cirrhosis in the general population. Cox proportional hazards
regression analysis was used to calculate relative risk (RR)
estimates and 95% conﬁdence intervals (CI), adjusted for
relevant covariates.
Results: Thirty nine cases of cirrhosis were identiﬁed in
a cohort of 1,737 HCT survivors, followed for a median of 6.1y
(1-33). Median age at HCT: 33.8y (0.6-74.9); median time to
cirrhosis: 6.0y (1-25.6); 64% were male; 41% Hispanic; 62%
underwent HCT<1992; Hepatitis C infection was present in
56.4%. Cumulative incidence of cirrhosis was 1.6% at 10 yrs
and 4.6% at 20 yrs post-HCT. The cohort was at a 15-fold
increased risk of cirrhosis (standardized incidence ratio [SIR]
15.0, CI:10.8-20.3) when compared to the general pop-
ulation. The risk was highest for patients who underwent
HCT<1992 (SIR¼27.9, CI:18.2-40.6); the risk remained
elevated among those transplanted 1992 (SIR¼8.7, CI:5.0-
13.8). Absolute excess risk for the entire cohort was 26.2 per
10,000 person-years of follow-up. Multivariable analysis
adjusted for age, gender, race/ethnicity, diagnosis, treatment
era, HCT conditioning, and GvHD, revealed older age at HCT
(>40 yrs [RR¼5.9, P < .01]) and total body irradiation (TBI
[RR¼14.4, P ¼ .01]) to be independent risk factors for
cirrhosis. Five-year survival following diagnosis of cirrhosis
was 38.2% (primary cause of death: liver failure in 84.6%)
Conclusions: The incidence of cirrhosis increases with time
from HCT. While the risk is higher among those transplanted
before 1992, recent HCT recipients remain at increased risk.
Older age at HCT and conditioning with TBI signiﬁcantly
increase risk of cirrhosis. These data form the basis for
